Cited 8 times in
Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장종희 | - |
dc.date.accessioned | 2014-12-19T17:10:59Z | - |
dc.date.available | 2014-12-19T17:10:59Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 2005-3711 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90929 | - |
dc.description.abstract | OBJECTIVE: This study was performed to determine the safety and outcome of concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide for Korean patients with a newly diagnosed glioblastoma. METHODS: Patients were recruited from four institutions between 2004 and 2007. The patients received fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks and daily temozolomide, followed by 6 cycles of adjuvant temozolomide. The primary endpoint was overall survival (OS) and the secondary endpoints were progression-free survival (PFS), response, and safety. RESULTS: A total of 103 patients were enrolled in this study. Ninety-six patients (93%) completed the CCRT and 54 patients (52%) received 6 cycles of adjuvant temozolomide. The response rate was 73% (53/73) and the tumor control rate was 92% (67/73). Of the 96 patients who completed the CCRT, the median OS was 18.0 months and the 1- and 2-year OS rates were 74 and 38%, respectively. The median PFS was 10.0 months and the 1- and 2-year PFS rates were 33 and 16%, respectively. The only significant prognostic factor of survival was the extent of surgical resection (p<0.05). CCRT resulted in grade 3 or 4 hematologic toxic effects in 8% of patients. No opportunistic infections were noted. CONCLUSION: This study is the first prospective multi-institutional report of CCRT and adjuvant chemotherapy with temozolomide for patients with a newly diagnosed glioblastoma in Korea. The current protocol may prolong the survival of Korean patients with a glioblastoma and may be tolerable in terms of toxicity. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | JOURNAL OF KOREAN NEUROSURGICAL SOCIETY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학) | - |
dc.contributor.googleauthor | Jin-Deok Joo | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Jeong Hoon Kim | - |
dc.contributor.googleauthor | Yong-Kil Hong | - |
dc.contributor.googleauthor | Young-Hoon Kim | - |
dc.contributor.googleauthor | Chae-Yong Kim | - |
dc.identifier.doi | 10.3340/jkns.2012.52.2.92 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03470 | - |
dc.relation.journalcode | J01520 | - |
dc.identifier.eissn | 1598-7876 | - |
dc.identifier.pmid | 23091665 | - |
dc.subject.keyword | Chemoradiotherapy | - |
dc.subject.keyword | Glioblastoma | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | Temozolomide | - |
dc.contributor.alternativeName | Chang, Jong Hee | - |
dc.contributor.affiliatedAuthor | Chang, Jong Hee | - |
dc.citation.volume | 52 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 92 | - |
dc.citation.endPage | 97 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN NEUROSURGICAL SOCIETY, Vol.52(2) : 92-97, 2012 | - |
dc.identifier.rimsid | 33222 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.